Últimas noticias sobre TKO Group Holdings (NYSE:TKO) Bolsa

TKO GROUP HOLDINGS INC

TKO Group Holdings

TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.

Time magazine

Long Ideas

Tech

Media

Trading Ideas

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GILD

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

TIME revela las 100 empresas más influyentes de 2025. Conoce las compañías en bolsa que lideran innovación y crecimiento este año.

Las empresas más influyentes de 2025 según TIME: ¿Cuáles están en bolsa?

Top 10 Shows On Netflix India This Week

Entertainment

Sports

Acciones de Netflix (NFLX) podrían subir si logra los derechos de transmisión de la UFC

News

El estreno de WWE Monday Night Raw en Netflix duplicó su audiencia anterior, atrayendo a 2,6 millones de hogares en EE.UU. en su primer episodio.

WWE Monday Night Raw debuta en Netflix con audiencia récord

Agreement strengthens one of the world's largest co-branded portfolios, enhancing priceless experiences for AAdvantage Mastercard cardmembers
American Airlines and Mastercard today announced an extension of their decades-long partnership, reinforcing a shared commitment to delivering more rewarding travel experiences and value through advanced payments technology and services.
"American is proud to collaborate with Mastercard to deliver best-in-class travel solutions for our AAdvantage&#xAE; co-branded credit cardmembers," said American's CEO Robert Isom. "Together, we are rewarding our mutual customers with travel experiences that make their journeys truly special."
The agreement secures Mastercard as the exclusive payment network partner for American's co-branded credit cards, building on nearly 40 years of collaboration between the two companies. Together, American and Mastercard will continue to enhance the AAdvantage&#xAE; program — American's industry-leading travel rewards program — while providing cardholders with seamless and personalized experiences on every trip.

American Airlines And Mastercard Extend Exclusive Partnership To Enhance AAdvantage Co-Branded Cardholder Travel Experiences

Barclays analyst Adam Seiden maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Equal-Weight and raises the price target from $381 to $387.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Cummins, Raises Price Target to $387

B of A Securities analyst Shaun Kelley maintains Ryman Hospitality Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy and raises the price target from $105 to $110.

B of A Securities Maintains Buy on Ryman Hospitality Props, Raises Price Target to $110

WIIM

GLXY

Galaxy Digital shares are trading higher after the company announced it has partnered with K Wave Media to accelerate Bitcoin treasury strategies and have access to greater institutional capital.

Connect Biopharma Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it plans to terminate the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas (the "Depositary"), and the holders and beneficial owners of American Depositary Shares ("ADSs") evidenced by American Depositary Receipts ("ADRs") issued thereunder (the "Deposit Agreement").
The ADR program and the Deposit Agreement are expected to terminate on or about September 2, 2025. At such time, the Company's ADRs will be mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. Immediately following the termination of the ADR program, the Company plans to list its ordinary shares on the Nasdaq Global Market ("Nasdaq") in substitution for its ADRs (the "Substitution Listing"). The Company expects that, upon the effectiveness of the Substitution Listing, its ADRs will cease to be listed on Nasdaq and the ordinary shares represented by the ADRs will commence trading on Nasdaq under the Company's existing symbol "CNTB".
The Company will instruct the Depositary to issue a termination notice to owners and holders of ADRs on or about August 18, 2025, which will provide more information regarding the termination of the ADR program.

CNTB

Connect Biopharma To Terminate ADR Program And List Ordinary Shares Directly On Nasdaq

Bernstein analyst Nikhil Devnani maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Outperform and raises the price target from $210 to $265.

Bernstein Maintains Outperform on DoorDash, Raises Price Target to $265

Barclays analyst Adam Seiden maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Equal-Weight and raises the price target from $335 to $383.

Barclays Maintains Equal-Weight on Caterpillar, Raises Price Target to $383

B of A Securities analyst Shaun Kelley maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Buy and raises the price target from $275 to $285.

B of A Securities Maintains Buy on Hilton Worldwide Holdings, Raises Price Target to $285

Cuprina Holdings (Cayman) Limited (NASDAQ:<a href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025.
Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first such marketing clearance in US history.&nbsp;This agreement gives Cuprina the right to manufacture, sell, use and distribute these maggots and associated dressings for use in maggot debridement therapy (MDT) in the United States.
Upon joining Cuprina, Dr. Sherman's roles and responsibilities are expected to include the following: Clinical Leadership on Bio-Therapeutics:
<ul>
<li>Serve as clinical and key opinion leader on maggot therapy, leech therapy, ichthyotherapy, and other company bio-therapeutic initiatives; and</li>
<li>Provide mentorship, insights, and scientific guidance to Cuprina and affiliated clinicians in adopting and expanding bio-therapeutic practices.</li>
</ul>
Training, Education and Awareness:
<ul>
<li>Co-develop, with Cuprina, a structured training and certification framework for bio-therapeutics;</li>
<li>Assist in designing the syllabus and modules for education and certification; and</li>
<li>Represent Cuprina as a speaker at conferences, seminars, and public events to raise awareness and advance the adoption of bio-therapeutics.</li>
</ul>
Regulatory and Clinical Trials Support:
<ul>
<li>Provide expert guidance and counsel in navigating regulatory requirements across Southeast Asia and the MENA region; and</li>
<li>Assist in designing and reviewing clinical trial protocols or supporting documentation when required by Cuprina.</li>
</ul>

Biotech

General

CUPR

Cuprina Secures Exclusive License For FDA-Cleared Medical Maggots, Appoints Dr. Ronald Sherman As Medical Director

Barclays analyst Brendan Lynch maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Overweight and lowers the price target from $59 to $52.

LINE

Barclays Maintains Overweight on Lineage, Lowers Price Target to $52

The positive FDA feedback allows for:
<ul>
<li>A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population</li>
<li>Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspected cause of&nbsp;Crohn's disease and its symptoms&nbsp;</li>
<li>RedHill has initiated two new collaborations with leading academic centers utilizing cutting-edge rapid and accurate MAP detection diagnostics – the lack of which has previously been a major barrier to advancing the Company's novel anti-MAP Crohn's disease program</li>
<li>Innovative design enables a smaller sample size allowing for lower study costs and faster time to completion</li>
</ul>
Funding for this ground-breaking program expected to be non-dilutive; Grant application submitted and discussions ongoing for additional non-dilutive financing
Patent protected through 2041, orally-administered RHB-204, a next-generation optimized formulation of&nbsp;RedHill's RHB-104 designed to further enhance tolerability, safety and patient adherence, is supported by positive RHB-104[2] Phase 3 safety and efficacy results, which delivered a statistically significant 64% improvement in efficacy[3]
Expected transferal of pediatric orphan drug designation to RHB-204 as well as potential for breakthrough therapy designation, fast track designation, additional regulatory exclusivity and priority review voucher
The&nbsp;multibillion-dollar Crohn's disease market is expected to expand significantly, with sales in the key markets growing from $13.6 billion in 2024 to over $19 billion in 2033[4], presenting significant commercial potential for new, paradigm changing, FDA-approved therapies
RALEIGH,&nbsp;N.C. and TEL AVIV, Israel, July 21, 2025 /PRNewswire/ --&nbsp;RedHill Biopharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received positive feedback from the U.S. Food and Drug Administration (FDA), following a scheduled Type C meeting, in which the FDA provided guidance on the pathway to approval for the Company's potentially groundbreaking RHB-204 Crohn's disease (CD) development program.

RDHL

RedHill Biopharma Receives FDA Guidance On Approval Path For RHB-204 Crohn's Disease Program Following Type C Meeting

Dividends

UPDATE: Announced July 18, 2025, SunLink Health Systems Declares Special Cash Dividend $0.10/Share

Trump Media & Technology shares are trading higher after the company announced it has accumulated approximately $2 billion in Bitcoin and related securities.

Bernstein analyst Nikhil Devnani maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and raises the price target from $55 to $60.

CART

Bernstein Maintains Outperform on Maplebear, Raises Price Target to $60

Asset Sales

GEVO

Gevo Sells Carbon Credits From North Dakota Asset; Amount Not Disclosed

Barclays analyst Anthony Powell maintains Americold Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COLD#NYSE">COLD</a>) with a Overweight and lowers the price target from $21 to $20.

COLD

Barclays Maintains Overweight on Americold Realty Trust, Lowers Price Target to $20

NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/NXPI/earnings">closing bell on Monday, July 21.</a>
Analysts expect the Eindhoven, the Netherlands-based company to report quarterly earnings at $2.66 per share, down from $3.20 per share in the year-ago period. NXP Semiconductors projects to report quarterly revenue at $2.9 billion, compared to $3.13 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 12, the company's board of directors approved the payment of an interim dividend of $1.014 per ordinary share for the second quarter.
NXP Semiconductors shares gained 0.6% to close at $225.90 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/nxpi/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Christopher Danely maintained a Buy rating and raised the price target from $210 to $275 on July 7, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating and boosted the price target from $225 to $250 on June 18, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating and increased the price target from $237 to $289 on June 12, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Truist Securities analyst William Stein maintained a Buy rating and slashed the price target from $258 to $230 on April 29, 2025. This analyst has an accuracy rate of 86%.</li>
<li>Barclays analyst Blayne Curtis maintained an Overweight rating and cut the price target from $230 to $190 on April 22, 2025. This analyst has an accuracy rate of 74%.</li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/NXPI/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21043602/image-266-1024x611.png" alt="" class="wp-image-993224" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21043602/image-266-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21043602/image-266-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21043602/image-266-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21043602/image-266.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

NXPI

NXP Semiconductors Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Peoples Bancorp of NC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBK#NASDAQ">PEBK</a>) reported quarterly earnings of $0.95 per share. This is a 6.74 percent increase over earnings of $0.89 per share from the same period last year. The company reported $22.29 million in sales this quarter. This is a 6.46 percent increase over sales of $20.94 million the same period last year.

PEBK

Peoples Bancorp of NC Q2 EPS $0.95 Up From $0.89 YoY, Sales $22.29M Up From $20.94M YoY

Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported upbeat earnings for the second <a href="https://www.benzinga.com/quote/SCHW/earnings">quarter on Friday</a>.
The company posted quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.26 per share. The company reported quarterly sales of $849.000 million which beat the analyst consensus estimate of $842.389 million.
Comerica shares gained 4.7% to close at $65.32 on Friday.
These analysts made changes to their price targets on Comerica following earnings announcement.
<ul class="wp-block-list">
<li>Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintained Comerica with an Outperform rating and raised the price target from $69 to $73.</li>
<li>Stephens &amp; Co. analyst Terry McEvoy maintained Comerica with an Equal-Weight rating and raised the price target from $61 to $68.</li>
</ul>
Considering buying SCHW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21090117/image-282-1024x575.png" alt="" class="wp-image-993619" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21090117/image-282-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21090117/image-282-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21090117/image-282-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21090117/image-282.png 1070w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

These Analysts Increase Their Forecasts On Comerica Following Upbeat Q2 Results

BON Enters Non-Exclusive Sales Distribution Agreement With Beijing Huahai Keyuan Technology Co.; 36 Months With Total Contract Value $22M

Leaders in The News: Siyata Mobile, Fubo, Lottery.com, Unusual Machines

Leaders in The News: BBAI, SYTA, FCEL, LTRY 

AI for Gaming and Military Applications, Clean Energy, and Digital Transformation of $340 Billion Global Lotto Market

Press Releases

AFTER SHATTERING RECORDS IN THE SPORTS AND ENTERTAINMENT CAPITAL OF THE WORLD, WRESTLEMANIA® RETURNS TO LAS VEGAS ON SATURDAY, APRIL 18 & SUNDAY, APRIL 19, 2026

Billion Dollar Sports Entertainment Facility Market Witnessing Significantly High Revenue Share

FRE Nicotine Pouches Partners with PBR in the Brand's Largest-Ever Sports Sponsorship

Esports World Cup Foundation Announces Partnership with IMG to Launch Flagship Broadcast Series EWC Spotlight

TKO to Announce Second Quarter 2025 Results

FIFA World Cup 26™ Hospitality Packages Now Available Across All Three Host Countries

WWE® & Fanatics Betting and Gaming to Produce WWE-Themed Online Casino Games in U.S.

BBAI

DKNG

FCEL

FUBO

LTRY

MSGS

SYTA

UMAC

VENU

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Entertainment Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Holdings

Walt Disney

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Media

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

K Wave Media

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Marcus

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

Starz Entertainment Corp. - Common Shares

Starz Entertainment

TKO Group Holdings, Inc. Class A Common Stock

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Comments

TKO Group Holdings

Noticias

Últimas noticias sobre TKO Group Holdings (NYSE:TKO) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL